Endogenous patient responses and the consistency principle in cost-effectiveness analysis

Liqun Liu1, Andrew J Rettenmaier1, Thomas R Saving1

  • 1Texas A&M University, College Station, TX (LL, AJR, TRS)

Insights

This study clarifies the consistency principle in cost-effectiveness analysis (CEA). Including or excluding costs and benefits of patient responses does not change CEA results, but including survival consumption and earnings is recommended.

Area of Science:

  • Health Economics
  • Medical Decision Making
  • Pharmacoeconomics

Background:

  • Medical interventions have direct costs and health benefits, but also indirect financial and health impacts.
  • Determining which costs and benefits to include in cost-effectiveness analysis (CEA) is crucial.
  • The consistency principle mandates including or excluding both costs and utility benefits of a change.

Purpose of the Study:

  • To address the consistency principle in CEA by distinguishing exogenous and endogenous changes.
  • To determine how to choose between exclusion/inclusion rules for CEA.
  • To clarify the treatment of consumption costs and earnings in CEA.

Main Methods:

  • Distinguishing exogenous (intervention-driven) and endogenous (patient response) changes.
  • Utilizing a lifetime utility maximization framework.
  • Analyzing the impact of inclusion/exclusion rules on CEA outcomes.

Main Results:

  • Excluding or including both costs and utility benefits of endogenous changes does not affect CEA results.
  • Welfare maximization supports including consumption costs and earnings in CEA.
  • The study provides guidance on applying the consistency principle.

Conclusions:

  • The consistency principle in CEA is clarified, particularly regarding endogenous changes.
  • Including consumption costs and earnings in CEA aligns with welfare maximization.
  • This research aids in more accurate and comprehensive economic evaluations of medical interventions.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...